TY - JOUR T1 - Report 21: Estimating COVID-19 cases and reproduction number in Brazil JF - medRxiv DO - 10.1101/2020.05.09.20096701 SP - 2020.05.09.20096701 AU - Thomas A Mellan AU - Henrique H Hoeltgebaum AU - Swapnil Mishra AU - Charlie Whittaker AU - Ricardo P Schnekenberg AU - Axel Gandy AU - H Juliette T Unwin AU - Michaela A C Vollmer AU - Helen Coupland AU - Iwona Hawryluk AU - Nuno Rodrigues Faria AU - Juan Vesga AU - Harrison Zhu AU - Michael Hutchinson AU - Oliver Ratmann AU - Melodie Monod AU - Kylie Ainslie AU - Marc Baguelin AU - Sangeeta Bhatia AU - Adhiratha Boonyasiri AU - Nicholas Brazeau AU - Giovanni Charles AU - Laura V Cooper AU - Zulma Cucunuba AU - Gina Cuomo-Dannenburg AU - Amy Dighe AU - Bimandra Djaafara AU - Jeff Eaton AU - Sabine L van Elsland AU - Richard FitzJohn AU - Keith Fraser AU - Katy Gaythorpe AU - Will Green AU - Sarah Hayes AU - Natsuko Imai AU - Ben Jeffrey AU - Edward Knock AU - Daniel Laydon AU - John Lees AU - Tara Mangal AU - Andria Mousa AU - Gemma Nedjati-Gilani AU - Pierre Nouvellet AU - Daniela Olivera AU - Kris V Parag AU - Michael Pickles AU - Hayley A Thompson AU - Robert Verity AU - Caroline Walters AU - Haowei Wang AU - Yuanrong Wang AU - Oliver J Watson AU - Lilith Whittles AU - Xiaoyue Xi AU - Lucy Okell AU - Ilaria Dorigatti AU - Patrick Walker AU - Azra Ghani AU - Steven Riley AU - Neil M Ferguson AU - Christl A. Donnelly AU - Seth Flaxman AU - Samir Bhatt Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/18/2020.05.09.20096701.abstract N2 - Brazil is an epicentre for COVID-19 in Latin America. In this report we describe the Brazilian epidemic using three epidemiological measures: the number of infections, the number of deaths and the reproduction number. Our modelling framework requires sufficient death data to estimate trends, and we therefore limit our analysis to 16 states that have experienced a total of more than fifty deaths. The distribution of deaths among states is highly heterogeneous, with 5 states—São Paulo, Rio de Janeiro, Ceará, Pernambuco and Amazonas—accounting for 81% of deaths reported to date. In these states, we estimate that the percentage of people that have been infected with SARS-CoV-2 ranges from 3.3% (95% CI: 2.8%-3.7%) in São Paulo to 10.6% (95% CI: 8.8%-12.1%) in Amazonas. The reproduction number (a measure of transmission intensity) at the start of the epidemic meant that an infected individual would infect three or four others on average. Following non-pharmaceutical interventions such as school closures and decreases in population mobility, we show that the reproduction number has dropped substantially in each state. However, for all 16 states we study, we estimate with high confidence that the reproduction number remains above 1. A reproduction number above 1 means that the epidemic is not yet controlled and will continue to grow. These trends are in stark contrast to other major COVID-19 epidemics in Europe and Asia where enforced lockdowns have successfully driven the reproduction number below 1. While the Brazilian epidemic is still relatively nascent on a national scale, our results suggest that further action is needed to limit spread and prevent health system overload.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work used the Cirrus UK National Tier-2 HPC Service at EPCC (http://www.cirrus.ac.uk) funded by the University of Edinburgh and EPSRC (EP/P020267/1). We would like to thank Amazon AWS and Microsoft Azure for computational credits. We would like to thank the Stan Development team for their constant support. We acknowledge the Medical Research Council and FAPESP (MR/S0195/1).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code used is publicly available. https://covid.saude.gov.br/ https://www.ibge.gov.br/ https://github.com/ImperialCollegeLondon/covid19model ER -